Alan Kaplan, MD
Urology · Baltimore, MDNPI 1013233642
Payments from drug & device makers
Across 31 payments — averaging $332.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- Medtronic$327
- Neotract Inc.$289
- Endo Pharmaceuticals Inc.$81
- AbbVie$76
- Boston Scientific$75
- plus $185 from 6 others
What the payments were for
- Consulting fees$9,26390%
- Travel & lodging$2773%
- Food & beverage$7557%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $9,263 |
| Medtronic(2 entities) | 6 | $327 |
| Neotract Inc. | 3 | $289 |
| Endo Pharmaceuticals Inc. | 1 | $81 |
| AbbVie(2 entities) | 3 | $76 |
| Boston Scientific | 3 | $75 |
| Ferring Pharmaceuticals Inc. | 5 | $62 |
| Dendreon Pharmaceuticals LLC | 2 | $50 |
| Zyla Life Sciences, Inc. | 1 | $23 |
| Amgen | 1 | $19 |
| Viiv Healthcare Company | 1 | $15 |
| Hollister Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,294 in reported general payments places this provider in the 65th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $27,222 |
| JardianceEmpagliflozin | 13 | $6,775 |
| PradaxaDabigatran Etexilate Mesylate | 13 | $2,822 |
| Levothyroxine Sodium | 228 | $1,723 |
| Bisoprolol Fumarate | 18 | $1,204 |
| Potassium Chloride | 28 | $1,203 |
| Risperidone OdtRisperidone | 12 | $532 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 13 | $431 |
| Donepezil Hcl | 68 | $431 |
| Atorvastatin Calcium | 101 | $428 |
| Memantine Hcl | 29 | $387 |
| ClopidogrelClopidogrel Bisulfate | 52 | $347 |
| Metoprolol Succinate | 71 | $319 |
| Tamsulosin Hcl | 31 | $287 |
| Dorzolamide Hcl | 16 | $282 |
Paid to pharmacies, not to this prescriber.
Other urology in Baltimore
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
- Benjamin LowentrittBaltimore$994K
- Kenneth LangerBaltimore$610K
- Arvin GeorgeBaltimore$518K
- Mohummad SiddiquiBaltimore$321K
- Christian PavlovichBaltimore$271K
- Arthur BurnettBaltimore$235K
- Brian MatlagaBaltimore$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.